Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
3(42.9%)
N/A
2(28.6%)
Phase 3
2(28.6%)
7Total
Phase 2(3)
N/A(2)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06657495Phase 2Recruiting

To Evaluate the Safety and Efficacy of TD0015 Pilulae in Patients with Knee Osteoarthritis

Role: lead

NCT03845348Phase 3Unknown

To Evaluate the Efficacy and Safety of Shampoo TD03 and TD07 in Scalp Diseases

Role: lead

NCT05249777Phase 3Completed

A Phase III, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TD0069 Capsule for Patients With Mild to Moderate COVID-19

Role: lead

NCT05082727Phase 2Unknown

Safety and Efficacy of Softgel KOVIR (TD0068) in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR)

Role: lead

NCT05044650Not ApplicableUnknown

Efficacy of KOVIR Capsule in the Combination Regimen With Background Treatment in COVID-19 Patients

Role: lead

NCT05042141Not ApplicableCompleted

Safety and Efficacy of KOVIR in the Combination Regimen With Background Treatment in COVID-19 Patients (KOVIR)

Role: lead

NCT03845959Phase 2Completed

A Trial of TD0019 in Treatment of Cervical Scapulohumeral Syndrome

Role: lead

All 7 trials loaded